By <a href="http://www.kslaw.com/attorney_dir/attorneybrief.asp?451" target="_blank" James Dabney Miller, a partner with the law firm King & Spalding LLP.
Marc J. Scheineson, a partner in the law firm of Reed Smith, LLP in Washington, D.C., argues that as a matter of good public policy and constitutional and statutory law, FDA must cease its attempts to stop drug companies from claiming different trade names for one drug with multiple uses.
By visiting our website, you agree to the use of tracking technologies, such as cookies, to improve site functionality, analyze web traffic, and record how you interact with our website.